- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06323174
Tutkimustutkimus, jolla selvitetään, kuinka paljon CagriSema alentaa verensokeria ja painoa lumelääkkeeseen verrattuna ihmisillä, joilla on tyypin 2 diabetes ja joita hoidetaan ruokavaliolla ja liikunnalla (REIMAGINE 1)
Samanaikaisesti annettujen Cagrilintide ja Semaglutide (CagriSema) s.c. teho ja turvallisuus. annoksina 2,4 mg/2,4 mg ja 1,0 mg/1,0 mg kerran viikossa verrattuna lumelääkkeeseen potilailla, joiden tyypin 2 diabetes ei ole riittävästi hallinnassa ruokavaliolla ja harjoituksella
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Bergamo, Italia, 24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Catanzaro, Italia, 88100
- Policlinico Mater Domini Università di Catanzaro
-
Milan, Italia, 20132
- IRCCS Ospedale San Raffaele Milano
-
Roma, Italia, 00161
- Azienda Ospealiero Universitaria Policlinico Umberto I
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 100853
- Chinese People's Liberation Army General Hospital-Endocrinology
-
-
Jiangsu
-
Nanjing, Jiangsu, Kiina, 210011
- The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
-
Zhenjiang, Jiangsu, Kiina, 212001
- The Affiliated Hospital of Jiangsu University-Endocrinology
-
-
Shandong
-
Ji'Nan, Shandong, Kiina, 250000
- Jinan Central Hospital
-
Jinan, Shandong, Kiina, 250000
- Jinan Central Hospital
-
-
-
-
-
Bialystok, Puola, 15-351
- Osteo-Medic s.c. A. Racewicz, J. Supronik
-
Bialystok, Puola, 15-797
- Renew Clinic Sp. z o.o.
-
Lodz, Puola, 90-338
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
-
Warsaw, Puola, 02-507
- Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
-
Warsaw, Puola, 00-710
- NBR Polska Tomasz Klodawski
-
Zamość, Puola, 22-400
- Velocity Nova Sp. z o.o.
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Puola, 35-055
- Centrum Medyczne Medyk Sp. z o.o.
-
-
-
-
-
Al Ahsa, Saudi-Arabia, 36428
- King Abdulaziz Hospital-Al Ahsa-National Guard
-
Jeddah, Saudi-Arabia, 21423
- National Guard Hospital - Jeddah
-
Riyadh, Saudi-Arabia, 11525
- King Fahad Medical City
-
Riyadh, Saudi-Arabia, 12372
- King Khaled University Hospital,King Saud Univ. Med. City
-
Riyadh, Saudi-Arabia, 12769
- King Salman Bin Abdulaziz Hospital
-
-
-
-
-
Belgrade, Serbia, 11080
- Clinical Hospital Center Bezanijska Kosa
-
Belgrade, Serbia, 11080
- Clinical Hospital Centre Zemun
-
Belgrade, Serbia, 11000
- CHC Zvezdara, Clinical department for endocrinology
-
Zaječar, Serbia, 19000
- Policlinic for diabetes
-
-
-
-
-
Budapest, Unkari, 1032
- Szent Margit Rendelőintézet Nonprofit Kft.
-
Budapest, Unkari, 1102
- PVN Kutató Kft.
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Unkari, 4025
- Belinus Bt.
-
-
Szabolcs-Szatmar Varmegye
-
Nyíregyháza, Szabolcs-Szatmar Varmegye, Unkari, 4405
- Borbánya Praxis E.Ü. Kft.
-
-
-
-
California
-
Huntington Park, California, Yhdysvallat, 90255
- Nat Res Inst Huntington Park
-
Northridge, California, Yhdysvallat, 91325
- Valley Clinical Trials, Inc.
-
Santa Ana, California, Yhdysvallat, 92701
- Southern California Dermatology
-
-
Florida
-
Hollywood, Florida, Yhdysvallat, 33024
- Encore Medical Research LLC
-
Orlando, Florida, Yhdysvallat, 32819
- Headlands Research Orlando
-
Weston, Florida, Yhdysvallat, 33331
- Encore Medical Research of Weston
-
-
Kansas
-
Newton, Kansas, Yhdysvallat, 67114
- Alliance for Multispec Res
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Troy, Michigan, Yhdysvallat, 48098
- Arcturus HC PLC Troy Med Res
-
-
New York
-
West Seneca, New York, Yhdysvallat, 14224
- Southgate Medical Group, LLP
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97210
- Summit Research Network Oregon Inc.
-
-
Tennessee
-
Kingsport, Tennessee, Yhdysvallat, 37660
- Holston Medical Group
-
-
Texas
-
Amarillo, Texas, Yhdysvallat, 79124
- Amarillo Medical Specialists
-
Austin, Texas, Yhdysvallat, 78704
- Elligo Clin Res Centre
-
Brownsville, Texas, Yhdysvallat, 78526
- Headlands Research Brownsville
-
Dallas, Texas, Yhdysvallat, 75230
- Velocity Clinical Res-Dallas
-
San Antonio, Texas, Yhdysvallat, 78233
- Northeast Clinical Research of San Antonio
-
Shavano Park, Texas, Yhdysvallat, 78231
- Consano Clinical Research, LLC
-
Sugar Land, Texas, Yhdysvallat, 77479
- Sugar Lakes Family Practice PA
-
Weslaco, Texas, Yhdysvallat, 78596
- Valley Diab. & Endo Comp Ctr
-
-
Virginia
-
Newport News, Virginia, Yhdysvallat, 23606
- TPMG Clinical Research
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Male or female
- Age 18 years or above at the time of signing the informed consent
- Diagnosed with type 2 diabetes >=30 days before screening
- HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
- Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening
Exclusion Criteria:
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
- Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
- Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: CagriSema Dose 2
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Placebo Comparator: Placebo Dose 2
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
|
Active Comparator: Cagrisema Dose 1
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Placebo Comparator: Placebo Dose 1
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in glycated haemoglobin (HbA1c)
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as percentage (%)-points. |
From baseline (week 0) to end of treatment (week 40)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Relative change in body weight
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured in %. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=15% body weight reduction
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Aikaikkuna: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
Aikaikkuna: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Change in Fasting Plasma Glucose (FPG)
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimoles per liter (mmol/L). |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=5% body weight reduction
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=20% body weight reduction
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in waist circumference
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured in centimeters (cm). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in systolic blood pressure (SBP)
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimeters of mercury (mmHg). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in diastolic blood pressure (DBP)
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured in mmHg. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Total cholesterol
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Triglycerides
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Free fatty acids
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Non-HDL cholesterol
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
Aikaikkuna: At end of study (week 52)
|
Measured as count of participants. |
At end of study (week 52)
|
|
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Physical Component Summary score
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Mental Component Summary score
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in leptin
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured in nanograms per milliliter (ng/mL). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in soluble leptin receptor
Aikaikkuna: From baseline (week 0) to end of treatment (week 40)
|
Measured in ng/mL. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of Treatment Emergent Adverse Events (TEAEs)
Aikaikkuna: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of events. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
Aikaikkuna: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Aikaikkuna: From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- NN9388-4895
- 2022-502677-42 (Muu tunniste: European Medical Agency (EMA))
- U1111-1283-0404 (Muu tunniste: World Health Organization (WHO))
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .